UB Paderborn / Katalog / Suche / in CDI

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

The Lancet (British edition), 2007-05, Vol.369 (9574), p.1693-1702

2007

Volltextzugriff (PDF)

Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults

Vaccine, 2015-07, Vol.33 (31), p.3766-3772

2015

Volltextzugriff (PDF)

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

The Pediatric infectious disease journal, 2007-12, Vol.26 (12), p.1099-1104

2007

Volltextzugriff (PDF)

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

Pediatrics (Evanston), 2007-01, Vol.119 (1), p.11-18

2007

Volltextzugriff (PDF)

Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine

The New England journal of medicine, 2006-01, Vol.354 (1), p.23-33

2006

Volltextzugriff (PDF)

Profile: PATH's Vaccine Development Global Program

Human vaccines & immunotherapeutics, 2012-06, Vol.8 (6), p.700-701

Boslego, John W.

2012

Volltextzugriff (PDF)

Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development

The Lancet (British edition), 2014-06, Vol.383 (9935), p.2180-2183

2014

Volltextzugriff (PDF)

Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults

Vaccine, 2020-09, Vol.38 (41), p.6442-6449

2020

Volltextzugriff (PDF)

PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries

Expert review of vaccines, 2012-08, Vol.11 (8), p.939-947

2012

Volltextzugriff (PDF)

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States

The Pediatric infectious disease journal, 2007-03, Vol.26 (3), p.221-227

2007

Volltextzugriff (PDF)

Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus– Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age

Vaccine, 2011-02, Vol.29 (6), p.1324-1331

2011

Volltextzugriff (PDF)

Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus– Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age

Vaccine, 2009-04, Vol.27 (19), p.2540-2547

2009

Volltextzugriff (PDF)

Protection against hepatitis A by an inactivated vaccine

JAMA : the journal of the American Medical Association, 1994-05, Vol.271 (17), p.1328

1994

Volltextzugriff (PDF)

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults

Human vaccines, 2009-02, Vol.5 (2), p.92-97

2009

Volltextzugriff (PDF)

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

The New England journal of medicine, 2007-05, Vol.356 (19), p.1928-1943

2007

Volltextzugriff (PDF)

Experimental Gonococcal Urethritis and Reinfection with Homologous Gonococci in Male Volunteers

Sexually transmitted diseases, 2001-10, Vol.28 (10), p.555-564

2001

Volltextzugriff (PDF)

Strategies for broad global access to pandemic influenza vaccines

Current topics in microbiology and immunology, 2009, Vol.333, p.471

2009

Volltextzugriff (PDF)

Path Pneumococcal Vaccine Project

Pediatric health, 2010-10, Vol.4 (5), p.471-478

2010

Volltextzugriff (PDF)

Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5–7 May 2014

Vaccine, 2015-11, Vol.33 (48), p.6503-6510

2015

Volltextzugriff (PDF)

Revaccination with a 23-Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

The Journal of infectious diseases, 2010-02, Vol.201 (4), p.525-533

2010

Volltextzugriff (PDF)

Post-licensure comparative study of unusual high-pitched crying and prolonged crying following COMVAX™ and placebo versus PedvaxHIB™ and RECOMBIVAX HB™ in healthy infants

Vaccine, 2002-12, Vol.21 (3), p.181-187

2002

Volltextzugriff (PDF)

Group B streptococcal vaccine for resource-poor countries

The Lancet (British edition), 2011-07, Vol.378 (9785), p.11-12

Schrag, Stephanie J

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial

Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine

Profile: PATH's Vaccine Development Global Program

Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development

Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults

PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States

Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus– Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age

Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus– Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age

Protection against hepatitis A by an inactivated vaccine

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Experimental Gonococcal Urethritis and Reinfection with Homologous Gonococci in Male Volunteers

Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life

Strategies for broad global access to pandemic influenza vaccines

Path Pneumococcal Vaccine Project

Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection

Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5–7 May 2014

Revaccination with a 23-Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

Post-licensure comparative study of unusual high-pitched crying and prolonged crying following COMVAX™ and placebo versus PedvaxHIB™ and RECOMBIVAX HB™ in healthy infants

Group B streptococcal vaccine for resource-poor countries

Suchergebnisse filtern